Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines to extend the curative power of bone marrow transplant and cell therapies to patients suffering from blood cancers, autoimmune diseases, and genetic diseases. Magenta has established a portfolio of first-in-class therapeutic development programs to address significant unmet medical needs that are inherent with the existing bone marrow transplant process. Magenta’s most advanced program, MGTA-456, is an allogeneic stem cell therapy that has completed Phase I clinical trials. The Company initiated a Phase II study of MGTA-456 in patients with inherited metabolic diseases (IMDs), such as Hurler’s diseases and leukodystrophies